Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Nuclear medicine communications

• Publication date

  1991-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00006231-199104000-00004PMID 2067740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Therapeutic Radionuclides: Production, Physical Characteristics, and Applications

  2013cites this paper
• Current Directions in Radiopharmaceutical Research and Development

  2011cites this paper
• 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience

  2008cites this paper
• Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies

  2007cites this paper
• Biodistribution , and Dosimetry of Specific and Control Radiolabeled Monoclonal Antibodies in Patients with Primary Head and Neck Squamous Cell Carcinoma

  2006cites this paper
• Radioimmunotherapy: no news from the newcomer

  2005cites this paper
• Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?

  2004cites this paper
• Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells

  2001cites this paper
• Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.

  2000cites this paper
• Use of radionuclides for the palliation of bone metastases.

  2000cites this paper
• Use of Monoclonal Antibodies for the Diagnosis and Treatment of Bladder Cancer

  1999cites this paper
• Targeted delivery of radiolabeled imaging and therapeutic agents: bifunctional radiopharmaceuticals.

  1999cites this paper
• Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration

  1998influential citation
• Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.

  1998cites this paper
• Tumour Targeting Using Peptides, Monoclonal Antibodies and Fragments

  1997cites this paper
• Towards the goal of cancer-specific imaging and therapy.

  1997cites this paper
• Tumour identification using radiopharmaceuticals.

  1997cites this paper
• Is there life after technetium: what is the potential for developing new broad-based radionuclides?

  1996cites this paper
• Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ-32P]-ATP

  1996cites this paper
• Immunoscintigraphy: Importance for researchers and patients.

  1996cites this paper
• Recombinant anti-human melanoma antibodies are versatile molecules.

  1996cites this paper
• Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.

  1996cites this paper
• Radiolabeled monoclonal antibodies in diagnosis and therapy of cancer. Summary and perspectives.

  1996cites this paper
• Therapeutic radionuclides: Making the right choice

  1996cites this paper
• Summary and Perspectives

  1996cites this paper
• Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.

  1995cites this paper
• Bacterial expression of a kemptide fusion protein facilitates 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment.

  1995cites this paper
• Radioimmunotherapy of Ovarian Cancer

  1995cites this paper
• Improved Control of Malignant Gliomas by Means of Intralesional Radioimmunotherapy

  1995cites this paper
• An Introduction to the Clinical Applications of Antibodies

  1995cites this paper
• The Tissue Characterisation of Malignancy with Radionuclide Studies

  1995cites this paper
• Nuclear medicine, state of the art and science

  1995cites this paper
• Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir.

  1995cites this paper
• Tumor imaging with monoclonal antibodies.

  1995cites this paper
• Technetium‐99m, rhenium‐186, and rhenium‐188 direct‐labeled antibodies

  1994cites this paper
• Tumour imaging with radiolabelled monoclonal antibodies.

  1994cites this paper
• Changes of serum alpha fetoprotein before and after radioimmunotherapy in patients with hepatocellular carcinoma

  1994cites this paper
• Approaches to improved antibody- and peptide-mediated targeting for imaging and therapy of cancer

  1994cites this paper
• A Practical Approach to Monoclonal Antibody Imaging

  1993cites this paper
• Radioimmunotherapy of Gastrointestinal Cancer and Glioblastomas

  1993cites this paper
• Selection of radionuclides for radioimmunotherapy.

  1993cites this paper
• Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.

  1993cites this paper
• Bifunctional antibodies and their potential clinical applications

  1992cites this paper
• Chapter 19. Monoclonal Antibodies in Therapy

  1992cites this paper
• Radioimmunoscintigraphy of ovarian cancer.

  1991cites this paper